Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AP30663 for Cardioversion in Atrial Fibrillation
NCT04571385Phase 2Completed
- Sponsor
- Acesion Pharma
- Start
- Sep 2019
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of AP30663 in Atrial fibrillation (AFib) (4 arms), sponsored by Acesion Pharma. Primary endpoint: Percentage of Participants Who Converted From Atrial Fibrillation (AF) Within 90 Minutes From Start of Infusion and Subsequently Had no AF Recurrence Within 1 Minute of Conversion From AF. Started Sep 2019; status: completed.
02
Drugs
AP30663
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT04571385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04571385.